NO20000407L - Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyre samt fremgangsmõter til behandling av hyperlipidemi - Google Patents
Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyre samt fremgangsmõter til behandling av hyperlipidemiInfo
- Publication number
- NO20000407L NO20000407L NO20000407A NO20000407A NO20000407L NO 20000407 L NO20000407 L NO 20000407L NO 20000407 A NO20000407 A NO 20000407A NO 20000407 A NO20000407 A NO 20000407A NO 20000407 L NO20000407 L NO 20000407L
- Authority
- NO
- Norway
- Prior art keywords
- nicotinic acid
- hmg
- coa reductase
- present
- hyperlipidemia
- Prior art date
Links
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 title abstract 15
- 239000011664 nicotinic acid Substances 0.000 title abstract 9
- 229960003512 nicotinic acid Drugs 0.000 title abstract 9
- 235000001968 nicotinic acid Nutrition 0.000 title abstract 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title abstract 4
- 208000031226 Hyperlipidaemia Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 title 1
- 150000002632 lipids Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 4
- 206010072268 Drug-induced liver injury Diseases 0.000 abstract 3
- 208000023137 Myotoxicity Diseases 0.000 abstract 3
- 206010039020 Rhabdomyolysis Diseases 0.000 abstract 3
- -1 nicotinic acid compound Chemical class 0.000 abstract 3
- 210000002966 serum Anatomy 0.000 abstract 3
- 239000007787 solid Substances 0.000 abstract 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 238000013265 extended release Methods 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003405 delayed action preparation Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 230000000444 normolipidemic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 239000007939 sustained release tablet Substances 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Den foreliggende oppfinnelse vedrører faste farmasøytiske kombinasjoner for oral administre- ring som omfatter nikotinsyre eller en nikotinsyreforbindelse eller blandinger derav i en form for forlenget frigjøring og en HMG-CoA reduktaseinhibitor, hvilken er egnet for å endre li- pidnivåer i subjekter som eksempelvis lider av hyperlipidemi og ateroskJerose, uten å forårsa- ke medisinindusert hepatotoksicitet, myopati eller rabdomyolyse. Den foreliggende oppfin- nelse vedrører også fremgangsmåter for å endre serumlipider i subjekter for eksempelvis å behandle hyperlipidemi i hyperlipidemiske pasienter, lipidemi i normolipidemiske pasienter som er diagnostisert med eller predisponert for kardiovaskulær sykdom, og ateroslderose, ved å administrere slike orale faste farmasøytiske kombinasjoner en gang pr. dag som en enkelt dose i løpet av kveldstimene, uten å forårsake medisinindusert hepatotoksicitet, myopati eller rabdomyolyse, eller uten å forårsake i det minste et påvistbar antall individers medisinindu- serte hepatotoksicitet, myopati eller rabdomyolyse til et slikt nivå at avslutning av slik terapi ville måtte kreves. Nærmere bestemt vedrører den foreliggende oppfinnelse orale faste far- masøytiske kombinasjoner som eksempelvis består av (1) en HMG-CoA reduktaseinhibitor for umiddelbar eller forlenget frigjøring, (2) nikotinsyre, en nikotinsyreforbindelse eller blan- dinger derav, og (3) et svellingsagens til dannelse av et preparat med vedholdende frigjøring for forlenget frigjøring av nikotinsyren eller nikotinsyreforbindelsen eller blandinger derav for nattlig eller kveldsdosering til reduksjon av serumlipider og øking av HDL-kolesterol. Ifølge den foreliggende oppfinnelse, og som et eksempel, beskrives et preparat for oral administre- ring i løpet av kveldstimene for å endre serumlipider og som består av nikotinsyre og hydrok- sypropylmetylcelloulose i form av en forlenget eller vedholdende frigjøringstablett eller cap- let som er belagt med et belegg som omfatter en HMG-CoA reduktaseinhibitor i en form for umiddelbar frigjøring. Også ifølge den foreliggende oppfinnelse, kan de farmasøytiske kom- binasjoner inkludere et ikke stereodalt anti-inflammatorisk agens for å redusere nikotinsyrens eller nikotinsyreforbindelsens evne til å provosere rødmingsreaksjoner hos individer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/903,871 US20010006644A1 (en) | 1997-07-31 | 1997-07-31 | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night |
| PCT/US1998/015989 WO1999006046A1 (en) | 1997-07-31 | 1998-07-31 | Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20000407D0 NO20000407D0 (no) | 2000-01-27 |
| NO20000407L true NO20000407L (no) | 2000-03-16 |
Family
ID=25418189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000407A NO20000407L (no) | 1997-07-31 | 2000-01-27 | Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyre samt fremgangsmõter til behandling av hyperlipidemi |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20010006644A1 (no) |
| EP (3) | EP1743644A1 (no) |
| AU (1) | AU8680098A (no) |
| BR (1) | BR9815549A (no) |
| CA (1) | CA2297764C (no) |
| IL (2) | IL134272A0 (no) |
| NO (1) | NO20000407L (no) |
| NZ (1) | NZ525486A (no) |
| WO (1) | WO1999006046A1 (no) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6811786B1 (en) * | 1999-04-01 | 2004-11-02 | Ganeden Biotech, Inc. | Methods for reducing cholesterol using Bacillus coagulans spores, systems and compositions |
| US7767203B2 (en) | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
| US20020169145A1 (en) * | 1998-10-14 | 2002-11-14 | Rajen Shah | Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent |
| US6569461B1 (en) | 1999-03-08 | 2003-05-27 | Merck & Co., Inc. | Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors |
| US7087597B1 (en) | 1999-10-12 | 2006-08-08 | Takeda Pharmaceutical Company Limited | Pyrimidine 5-carboxamide compounds, process for producing the same and use thereof |
| IL149422A0 (en) * | 1999-11-03 | 2002-11-10 | Smith Howard J & Ass Pty Ltd | Oral pharmaceutical compositions for liver therapy |
| US20020090622A1 (en) * | 2000-08-23 | 2002-07-11 | Monisola Adeokun | Chemical compounds |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| AR035533A1 (es) | 2001-01-26 | 2004-06-02 | Schering Corp | Uso de por lo menos un inhibidor de la absorcion de los esteroles o sus sales, solvatos, prodrogas farmaceuticamente aceptables o mezclas de los mismos para la preparacion de un medicamento para el tratamiento de la sitosterolemia, composiciones farmaceuticas, el uso de dichas composiciones para la |
| IL156445A0 (en) | 2001-01-26 | 2004-01-04 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| MXPA04002573A (es) | 2001-09-21 | 2004-06-18 | Schering Corp | Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol. |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| AU2002244881A1 (en) * | 2002-03-22 | 2003-10-08 | Ranbaxy Laboratories Limited | Controlled release drug delivery system of pravastatin |
| US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
| WO2004043457A1 (en) | 2002-11-06 | 2004-05-27 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| JP2006519869A (ja) | 2003-03-07 | 2006-08-31 | シェーリング コーポレイション | 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用 |
| EP1601668B1 (en) | 2003-03-07 | 2008-08-27 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CA2517572C (en) | 2003-03-07 | 2011-12-13 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| AR041089A1 (es) * | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| EP1653926A1 (en) * | 2003-08-04 | 2006-05-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US20050118370A1 (en) | 2003-08-18 | 2005-06-02 | Medtronic Vascular, Inc. | Hyper-elastic, high strength dilatation balloon made from multi-block copolymers |
| WO2005030185A2 (en) * | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| WO2005041878A2 (en) * | 2003-10-29 | 2005-05-12 | Tawakol Raif M D | Compositions and methods for increasing hdl and hdl-2b levels |
| ATE428411T1 (de) * | 2003-11-07 | 2009-05-15 | Jj Pharma Inc | Hdl-verstärkende kombinationstherapie-komplexe |
| PL364348A1 (en) * | 2004-01-12 | 2005-07-25 | PHARMENA Sp.z o.o. | Application of quaternary pyridine salts as vessel protection agent |
| CA2601762A1 (en) * | 2005-02-03 | 2006-08-10 | Pfizer Products Inc. | Dosage forms providing controlled and immediate release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| AU2006329564A1 (en) | 2005-07-11 | 2007-07-05 | Pharmena North America Inc. | Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| PT2026651E (pt) * | 2006-03-08 | 2013-06-04 | Cortria Corp | Terapia combinada com inibidores cox não selectivos para prevenir lesões gástricas relacionadas com a cox |
| EP2081550B2 (en) | 2006-03-09 | 2021-05-26 | Reliant Pharmaceuticals, Inc. | Coating capsules with active pharmaceutical ingredients |
| EP1911441A3 (en) * | 2006-10-11 | 2008-08-06 | Lupin Limited | Controlled release color stable pharmaceutical dosage form of HMG-COA reductase inhibitors, free of alkalizing or buffering agents |
| WO2008091870A2 (en) * | 2007-01-24 | 2008-07-31 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions comprising atorvastatin and nicotinic acid |
| US20100260841A1 (en) * | 2007-02-08 | 2010-10-14 | Paolini John F | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| WO2008100249A1 (en) * | 2007-02-13 | 2008-08-21 | Kos Life Sciences, Inc. | Low flush niacin formulation |
| IS8612A (is) * | 2007-02-19 | 2008-08-20 | Actavis Group Ptc Ehf. | Stöðugar statínlyfjasamsetningar |
| WO2008156561A1 (en) * | 2007-06-12 | 2008-12-24 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of statin-induced myopathy |
| US20090004285A1 (en) * | 2007-06-29 | 2009-01-01 | Liangping Yu | Stable non-disintegrating dosage forms and method of making same |
| US8404275B2 (en) * | 2007-07-01 | 2013-03-26 | Vitalis Llc | Combination tablet with chewable outer layer |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| PL2318035T3 (pl) | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| EP2334295B1 (en) * | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| KR20170005191A (ko) | 2009-01-06 | 2017-01-11 | 큐어론 엘엘씨 | 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법 |
| CN102300989B (zh) | 2009-01-06 | 2015-12-09 | 柯尔朗恩有限责任公司 | 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法 |
| SI2395991T1 (sl) | 2009-02-10 | 2013-12-31 | Amarin Pharmaceuticals Ireland Limited | Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| WO2010126579A1 (en) * | 2009-04-27 | 2010-11-04 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of statin-induced myopathy |
| NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| US8568743B2 (en) | 2009-04-29 | 2013-10-29 | Ganeden Biotech, Inc. | Inactivated bacterial cell formulation |
| SG10201605794PA (en) | 2009-04-29 | 2016-09-29 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| EP3318255B1 (en) | 2009-06-15 | 2021-03-10 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating stroke in a subject on concomitant statin therapy |
| AU2010298222B2 (en) | 2009-09-23 | 2017-01-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11235008B2 (en) | 2011-03-31 | 2022-02-01 | Ganeden Biotech, Inc. | Probiotic sports nutrition compositions |
| US8980252B2 (en) | 2011-04-21 | 2015-03-17 | Curemark Llc | Methods of treatment of schizophrenia |
| CA2853804C (en) | 2011-10-28 | 2021-06-01 | Vitalis Llc | Anti-flush compositions |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| ES2891473T3 (es) | 2012-01-06 | 2022-01-28 | Amarin Pharmaceuticals Ie Ltd | Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| NZ727849A (en) | 2012-06-29 | 2018-06-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
| US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| AU2018250823A1 (en) | 2017-04-10 | 2019-10-17 | Curemark, Llc | Compositions for treating addiction |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| LT3750536T (lt) | 2018-09-24 | 2026-03-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL265428A (no) * | 1960-06-06 | |||
| US3524001A (en) * | 1965-03-04 | 1970-08-11 | Upjohn Co | Compositions and method for reducing free fatty acid and cholesterol in the blood of mammals with 3,5 - disubstituted isoxazoles |
| US3674836A (en) | 1968-05-21 | 1972-07-04 | Parke Davis & Co | 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof |
| US4027009A (en) | 1973-06-11 | 1977-05-31 | Merck & Co., Inc. | Compositions and methods for depressing blood serum cholesterol |
| JPS5612114B2 (no) | 1974-06-07 | 1981-03-18 | ||
| US4166902A (en) * | 1974-10-14 | 1979-09-04 | Paolo Ferruti | High polymers containing nicotinic acid, process for their preparation and their use |
| JPS53147073A (en) | 1977-05-24 | 1978-12-21 | Sankyo Co Ltd | Mevalonolactone derivatives |
| US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| JPS57185275A (en) | 1981-05-07 | 1982-11-15 | Sankyo Co Ltd | Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives |
| US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US4499289A (en) | 1982-12-03 | 1985-02-12 | G. D. Searle & Co. | Octahydronapthalenes |
| CA1327360C (en) | 1983-11-14 | 1994-03-01 | William F. Hoffman | Oxo-analogs of mevinolin-like antihypercholesterolemic agents |
| US4588820A (en) | 1984-06-11 | 1986-05-13 | Merck & Co., Inc. | Process for epimerization at C6 of 3,4,5,6-tetrahydro-2H-pyran-2-one |
| US4613610A (en) | 1984-06-22 | 1986-09-23 | Sandoz Pharmaceuticals Corp. | Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives |
| HUT39142A (en) | 1984-07-24 | 1986-08-28 | Sandoz Ag | Process for producing naphtyl-analogues of mevalolactone and derivatives and pharmaceutical compositions containing them |
| US4686237A (en) | 1984-07-24 | 1987-08-11 | Sandoz Pharmaceuticals Corp. | Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof |
| US4647576A (en) | 1984-09-24 | 1987-03-03 | Warner-Lambert Company | Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis |
| EP0216785B1 (en) | 1984-12-04 | 1991-01-30 | Sandoz Ag | Indene analogs of mevalonolactone and derivatives thereof |
| US4668794A (en) | 1985-05-22 | 1987-05-26 | Sandoz Pharm. Corp. | Intermediate imidazole acrolein analogs |
| US4895558A (en) | 1985-07-15 | 1990-01-23 | University Of Queensland | Autologous plasma delipidation using a continuous flow system |
| HUT48208A (en) | 1985-10-25 | 1989-05-29 | Sandoz Ag | Process for producing heterocyclic analogues of mevalolactone derivatives and pharmaceutical compositions comprising such compounds |
| US4696237A (en) | 1986-02-11 | 1987-09-29 | Pullman Rail Leasing Incorporated | Multiple hopper rail car with offset vertical weld from conversion |
| FR2596393B1 (fr) | 1986-04-01 | 1988-06-03 | Sanofi Sa | Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant |
| US5110940A (en) | 1987-02-25 | 1992-05-05 | Bristol-Myers Company | Antihypercholesterolemic tetrazole compounds |
| IE63715B1 (en) | 1987-05-22 | 1995-06-14 | Squibb & Sons Inc | Phosphorus-containing hmg-coa reductase inhibitors |
| FI89493C (fi) | 1987-05-22 | 1993-10-11 | Squibb & Sons Inc | Foerfarande foer framstaellning av terapeutiskt aktiva, fosforhaltiga inhibitorer av hmg-coa-reduktas och vid foerfarandet anvaendbar ny mellanprodukt |
| US4759923A (en) | 1987-06-25 | 1988-07-26 | Hercules Incorporated | Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives |
| US4965252A (en) | 1988-06-28 | 1990-10-23 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination compositions of guar gum and niacin |
| US4911917A (en) | 1988-06-28 | 1990-03-27 | Hauser-Kuhrts, Inc. | Cholesterol-lowering combination comopsitions of magnesium salt and niacin |
| US5023245A (en) | 1987-11-10 | 1991-06-11 | Hauser-Kuhrts, Inc. | Improved niacin formulation |
| US5049696A (en) | 1988-04-11 | 1991-09-17 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4866058A (en) | 1988-07-27 | 1989-09-12 | Izydore Robert A | Method for control of hyperlipidemia |
| IT1226726B (it) | 1988-07-29 | 1991-02-05 | Zambon Spa | Composti attivi come inibitori della biosintesi del colesterolo. |
| US5196440A (en) | 1988-07-29 | 1993-03-23 | Zambon Group S.P.A. | Compounds active as inhibitors of the cholesterol biosynthesis |
| US5011947A (en) | 1988-08-25 | 1991-04-30 | Bristol-Myers | Antihypercholesterolemic alkylene compounds |
| CA2003478A1 (en) * | 1988-12-12 | 1990-06-12 | Leonard G. Dennick | Combination of an hmg coa reductase inhibitor and other type of serum cholesterol reducing agent and method for lowering serum cholesterol using such combination |
| US5260305A (en) * | 1988-12-12 | 1993-11-09 | E. R. Squibb & Sons, Inc. | Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination |
| US5099035A (en) | 1989-02-27 | 1992-03-24 | E. R. Squibb & Sons, Inc. | Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
| US5166364A (en) | 1989-02-27 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Mevinic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
| US5126145A (en) | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| US5268181A (en) | 1989-04-13 | 1993-12-07 | Upsher-Smith Laboratories, Inc. | Method of using niacin to control nocturnal cholesterol synthesis |
| US5010105A (en) | 1989-06-09 | 1991-04-23 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4970221A (en) | 1989-07-28 | 1990-11-13 | E. R. Squibb & Sons, Inc. | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
| US5106992A (en) | 1989-07-28 | 1992-04-21 | E. R. Squibb & Sons, Inc. | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
| US5126348A (en) * | 1989-09-26 | 1992-06-30 | The University Of Colorado Foundation, Inc. | Bioavailability enhancers |
| US5189180A (en) | 1989-09-28 | 1993-02-23 | E. R. Squibb & Sons, Inc. | Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates |
| US5025017A (en) | 1989-09-28 | 1991-06-18 | E. R. Squibb & Sons, Inc. | Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates |
| US5217992A (en) | 1989-10-04 | 1993-06-08 | Bristol-Myers Squibb Company | Tocotrienols in the treatment of hypercholesterolemia, hyperlipidemia and thromboembolic disorders |
| IT1237793B (it) | 1989-12-21 | 1993-06-17 | Zambon Spa | Composti attivi come inibitori dell'enzima hmg-coa reduttasi |
| US5049577A (en) | 1990-01-29 | 1991-09-17 | E. R. Squibb & Sons, Inc. | 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith |
| US5200424A (en) | 1990-08-28 | 1993-04-06 | Hoechst Aktiengesellschaft | Use of 10-membered ring lactones as lipid regulators |
| CA2052014A1 (en) * | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| JPH04193836A (ja) * | 1990-11-26 | 1992-07-13 | Banyu Pharmaceut Co Ltd | 抗高脂血症剤 |
| US5135935A (en) * | 1991-05-17 | 1992-08-04 | Merck & Co., Inc. | Squalene synthetase inhibitors |
| US5840339A (en) * | 1991-07-30 | 1998-11-24 | Kunin; Robert | Blood cholesterol reducing pharmaceutical composition |
| US5157134A (en) | 1992-03-12 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Dihydroxyheptanoic acids containing an oxabicycloheptane nucleus useful as antihypercholesterolemic agents |
| US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
| WO1994007485A1 (en) * | 1992-10-06 | 1994-04-14 | Merck & Co., Inc. | Zaragozic acid derivatives and methods of treating hypercholesterolemia, fungal growth, and cancer therewith |
| US5662934A (en) * | 1993-01-05 | 1997-09-02 | Najarian; Thomas | Compositions and methods for lowering cholesterol while maintaining antioxidant levels |
| US6129930A (en) * | 1993-09-20 | 2000-10-10 | Bova; David J. | Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night |
| US6080428A (en) * | 1993-09-20 | 2000-06-27 | Bova; David J. | Nicotinic acid compositions for treating hyperlipidemia and related methods therefor |
| EP0643965B1 (en) * | 1993-09-20 | 2013-05-08 | Abbott Laboratories | Nicotinic acid compositions for treating hyperlipidemia |
| GB2292885A (en) * | 1994-09-08 | 1996-03-13 | Merck & Co Inc | Method of treating hyperlipidemia |
| US5773453A (en) * | 1995-04-19 | 1998-06-30 | Vanderbilt University | Methods for administration of antilipemic drugs |
| AU5787996A (en) * | 1995-04-19 | 1996-11-07 | Lipoprotein Technologies, Inc. | Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs |
| US6469035B1 (en) * | 1997-07-31 | 2002-10-22 | Eugenio A. Cefali | Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid |
-
1997
- 1997-07-31 US US08/903,871 patent/US20010006644A1/en not_active Abandoned
-
1998
- 1998-07-31 AU AU86800/98A patent/AU8680098A/en not_active Abandoned
- 1998-07-31 NZ NZ525486A patent/NZ525486A/en unknown
- 1998-07-31 EP EP06017425A patent/EP1743644A1/en not_active Withdrawn
- 1998-07-31 CA CA002297764A patent/CA2297764C/en not_active Expired - Lifetime
- 1998-07-31 BR BR9815549-0A patent/BR9815549A/pt not_active Application Discontinuation
- 1998-07-31 EP EP98938227A patent/EP1003515A1/en not_active Withdrawn
- 1998-07-31 EP EP06017607A patent/EP1743630A3/en not_active Withdrawn
- 1998-07-31 WO PCT/US1998/015989 patent/WO1999006046A1/en not_active Ceased
- 1998-07-31 IL IL13427298A patent/IL134272A0/xx active IP Right Grant
-
2000
- 2000-01-27 IL IL134272A patent/IL134272A/en not_active IP Right Cessation
- 2000-01-27 NO NO20000407A patent/NO20000407L/no not_active Application Discontinuation
-
2005
- 2005-01-05 US US11/071,099 patent/US20050255158A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL134272A (en) | 2006-08-20 |
| EP1003515A1 (en) | 2000-05-31 |
| IL134272A0 (en) | 2001-04-30 |
| WO1999006046A1 (en) | 1999-02-11 |
| US20050255158A1 (en) | 2005-11-17 |
| AU8680098A (en) | 1999-02-22 |
| CA2297764A1 (en) | 1999-02-11 |
| WO1999006046A9 (en) | 1999-04-29 |
| NZ525486A (en) | 2005-10-28 |
| EP1743630A3 (en) | 2008-12-03 |
| EP1743644A1 (en) | 2007-01-17 |
| EP1743630A2 (en) | 2007-01-17 |
| NO20000407D0 (no) | 2000-01-27 |
| BR9815549A (pt) | 2004-06-22 |
| CA2297764C (en) | 2006-01-10 |
| US20010006644A1 (en) | 2001-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20000407L (no) | Kombinasjoner av HMG-COA reduktase inhibitorer og nikotinsyre samt fremgangsmõter til behandling av hyperlipidemi | |
| WO1999006035A3 (en) | COMBINATIONS OF HMG-CoA REDUCTASE INHIBITORS AND NICOTINIC ACID COMPOUNDS AND METHODS FOR TREATING HYPERLIPIDEMIA ONCE A DAY AT NIGHT | |
| Garnett | Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors | |
| Hsu et al. | Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia | |
| JPH02500107A (ja) | 即効性／強化された鎮痛作用 | |
| EP0336851B1 (fr) | Composition pharmaceutique pour administration orale à base d'un dérivé d'acide diphosphonique | |
| JP2000515526A (ja) | Ｍｔｐ阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法 | |
| EP0401705A2 (en) | Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease | |
| CA2224528A1 (fr) | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations | |
| CA2191789A1 (fr) | Composes biaromatiques portant un groupement adamantyl en ortho, compositions pharmaceutiques et cosmetiques les contenant et utilisations de ces compositions | |
| CA2238465A1 (fr) | Composes triaromatiques, compositions les contenant et utilisations | |
| CA2039763A1 (en) | Combination of pravastatin and a fibric acid derivative, and method for treating dyslipidemia using such combination | |
| AU2001242985B2 (en) | New combination of a betablocker and a cholesterol-lowering agent | |
| JP2004534094A (ja) | 二日酔いに有効な組成物及びそのための使用 | |
| Pan et al. | Pharmacokinetics of pravastatin in elderly versus young men and women | |
| Boccuzzi et al. | Long term experience with simvastatin | |
| CA2291650A1 (fr) | Nouveaux composes heteroethynylenes et compositions pharmaceutiques et cosmetiques les contenant | |
| CN100482645C (zh) | 逆转和预防心血管疾病的方法 | |
| CA2112195A1 (en) | Preventive and therapeutic agent for arteriosclerosis | |
| Metz et al. | Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction | |
| EP1296716B1 (en) | Use of a beta-blocker for the treatment of atherosclerosis | |
| FR2515962A1 (fr) | Preparations medicamenteuses contenant un derive d'acide tetraiodothyrocarboxylique notamment pour le traitement de l'hypercholesterolemie | |
| JPH05504971A (ja) | バムブテロールを含む脂質低下用医薬組成物 | |
| JPH02235820A (ja) | 血清コレステロール低下剤 | |
| JP2015522626A (ja) | レルカニジピンとアトルバスタチンの複合製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |